<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33847020</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-8081</ISSN><JournalIssue CitedMedium="Internet"><Volume>47</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Mar</Month></PubDate></JournalIssue><Title>BioFactors (Oxford, England)</Title><ISOAbbreviation>Biofactors</ISOAbbreviation></Journal><ArticleTitle>Long-COVID syndrome-associated brain fog and chemofog: Luteolin to the rescue.</ArticleTitle><Pagination><StartPage>232</StartPage><EndPage>241</EndPage><MedlinePgn>232-241</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/biof.1726</ELocationID><Abstract><AbstractText>COVID-19 leads to severe respiratory problems, but also to long-COVID syndrome associated primarily with cognitive dysfunction and fatigue. Long-COVID syndrome symptoms, especially brain fog, are similar to those experienced by patients undertaking or following chemotherapy for cancer (chemofog or chemobrain), as well in patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) or mast cell activation syndrome (MCAS). The pathogenesis of brain fog in these illnesses is presently unknown but may involve neuroinflammation via mast cells stimulated by pathogenic and stress stimuli to release mediators that activate microglia and lead to inflammation in the hypothalamus. These processes could be mitigated by phytosomal formulation (in olive pomace oil) of the natural flavonoid luteolin.</AbstractText><CopyrightInformation>&#xa9; 2021 International Union of Biochemistry and Molecular Biology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Theoharides</LastName><ForeName>Theoharis C</ForeName><Initials>TC</Initials><Identifier Source="ORCID">0000-0002-1598-460X</Identifier><AffiliationInfo><Affiliation>Laboratory of Molecular Immunopharmacology and Drug Discovery, Department of Immunology, Tufts University School of Medicine, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Tufts University School of Medicine and Tufts Medical Center, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Tufts University School of Medicine and Tufts Medical Center, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>BrainGate, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cholevas</LastName><ForeName>Christos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>BrainGate, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polyzoidis</LastName><ForeName>Konstantinos</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>BrainGate, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Politis</LastName><ForeName>Antonios</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>First Department of Psychiatry, Eginition Hospital, National and Kapodistrian University, Athens, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Biofactors</MedlineTA><NlmUniqueID>8807441</NlmUniqueID><ISSNLinking>0951-6433</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>KUX1ZNC9J2</RegistryNumber><NameOfSubstance UI="D047311">Luteolin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047311" MajorTopicYN="N">Luteolin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008407" MajorTopicYN="N">Mast Cells</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">brain fog</Keyword><Keyword MajorTopicYN="N">chemotherapy</Keyword><Keyword MajorTopicYN="N">coronavirus</Keyword><Keyword MajorTopicYN="N">cytokines</Keyword><Keyword MajorTopicYN="N">fatigue</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">mast cells</Keyword><Keyword MajorTopicYN="N">microglia</Keyword></KeywordList><CoiStatement>Theoharis C. Theoharides is the Scientific Director of and shareholder in Algonot, LLC (Sarasota, FL), which develops and markets flavonoid&#x2010;containing dietary supplements. He is also the recipient of US Patent No. 8,268,365, &#x201c;Anti&#x2010;inflammatory compositions for treating brain inflammation.&#x201d; The other authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>7</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33847020</ArticleId><ArticleId IdType="pmc">PMC8250989</ArticleId><ArticleId IdType="doi">10.1002/biof.1726</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ye Q, Wang B, Mao J. The pathogenesis and treatment of the &#x2018;cytokine Storm&#x2019; in COVID&#x2010;19. J Infect. 2020;80(6):607&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7194613</ArticleId><ArticleId IdType="pubmed">32283152</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7190990</ArticleId><ArticleId IdType="pubmed">32217835</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, et al. Induction of pro&#x2010;inflammatory cytokines (IL&#x2010;1 and IL&#x2010;6) and lung inflammation by Coronavirus&#x2010;19 (COVI&#x2010;19 or SARS&#x2010;CoV&#x2010;2): anti&#x2010;inflammatory strategies. J Biol Regul Homeost Agents. 2020;34(2):327&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">32171193</ArticleId></ArticleIdList></Reference><Reference><Citation>Giamarellos&#x2010;Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N, et al. Complex immune dysregulation in COVID&#x2010;19 patients with severe respiratory failure. Cell Host Microbe. 2020;27(6):992&#x2013;1000.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7172841</ArticleId><ArticleId IdType="pubmed">32320677</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine storm in COVID&#x2010;19: the current evidence and treatment strategies. Front Immunol. 2020;11:1708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7365923</ArticleId><ArticleId IdType="pubmed">32754163</ArticleId></ArticleIdList></Reference><Reference><Citation>Paces J, Strizova Z, Smrz D, Cerny J. COVID&#x2010;19 and the immune system. Physiol Res. 2020;69(3):379&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8648321</ArticleId><ArticleId IdType="pubmed">32469225</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragab D, Salah EH, Taeimah M, Khattab R, Salem R. The COVID&#x2010;19 cytokine storm; what we know so far. Front Immunol. 2020;11:1446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7308649</ArticleId><ArticleId IdType="pubmed">32612617</ArticleId></ArticleIdList></Reference><Reference><Citation>Herold T, Jurinovic V, Arnreich C, Lipworth BJ, Hellmuth JC, von Bergwelt&#x2010;Baildon M, et al. Elevated levels of IL&#x2010;6 and CRP predict the need for mechanical ventilation in COVID&#x2010;19. J Allergy Clin Immunol. 2020;146(1):128&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233239</ArticleId><ArticleId IdType="pubmed">32425269</ArticleId></ArticleIdList></Reference><Reference><Citation>Han H, Ma Q, Li C, Liu R, Zhao L, Wang W, et al. Profiling serum cytokines in COVID&#x2010;19 patients reveals IL&#x2010;6 and IL&#x2010;10 are disease severity predictors. Emerg Microbes Infect. 2020;9(1):1123&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7473317</ArticleId><ArticleId IdType="pubmed">32475230</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzoni A, Salvati L, Maggi L, Capone M, Vanni A, Spinicci M, et al. Impaired immune cell cytotoxicity in severe COVID&#x2010;19 is IL&#x2010;6 dependent. J Clin Invest. 2020;130(9):4694&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7456250</ArticleId><ArticleId IdType="pubmed">32463803</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, Li L, Xu M, Wu J, Luo D, Zhu YS, et al. Prognostic value of interleukin&#x2010;6, C&#x2010;reactive protein, and procalcitonin in patients with COVID&#x2010;19. J Clin Virol. 2020;127:104370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7194648</ArticleId><ArticleId IdType="pubmed">32344321</ArticleId></ArticleIdList></Reference><Reference><Citation>Copaescu A, Smibert O, Gibson A, Phillips EJ, Trubiano JA. The role of IL&#x2010;6 and other mediators in the cytokine storm associated with SARS&#x2010;CoV&#x2010;2 infection. J Allergy Clin Immunol. 2020;146(3):518&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7471766</ArticleId><ArticleId IdType="pubmed">32896310</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti P, Caraffa A, Gallenga CE, Ross R, Kritas SK, Frydas I, et al. Coronavirus&#x2010;19 (SARS&#x2010;CoV&#x2010;2) induces acute severe lung inflammation via IL&#x2010;1 causing cytokine storm in COVID&#x2010;19: a promising inhibitory strategy. J Biol Regul Homeost Agents. 2020;34(6):1971&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">33016027</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin M. Childhood multisystem inflammatory syndrome &#x2010; a new challenge in the pandemic. N Engl J Med. 2020;383(4):393&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7346677</ArticleId><ArticleId IdType="pubmed">32598829</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. 2020;383(4):334&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7346765</ArticleId><ArticleId IdType="pubmed">32598831</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowley AH. Understanding SARS&#x2010;CoV&#x2010;2&#x2010;related multisystem inflammatory syndrome in children. Nat Rev Immunol. 2020;20(8):453&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7296515</ArticleId><ArticleId IdType="pubmed">32546853</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K, et al. COVID&#x2010;19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis. 2020;20(11):e276&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7431129</ArticleId><ArticleId IdType="pubmed">32818434</ArticleId></ArticleIdList></Reference><Reference><Citation>Consiglio CR, Cotugno N, Sardh F, Pou C, Amodio D, Rodriguez L, et al. The immunology of multisystem inflammatory syndrome in children with COVID&#x2010;19. Cell. 2020;183(4):968&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7474869</ArticleId><ArticleId IdType="pubmed">32966765</ArticleId></ArticleIdList></Reference><Reference><Citation>Galeotti C, Bayry J. Autoimmune and inflammatory diseases following COVID&#x2010;19. Nat Rev Rheumatol. 2020;16(8):413&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7271827</ArticleId><ArticleId IdType="pubmed">32499548</ArticleId></ArticleIdList></Reference><Reference><Citation>Canna SW, Cron RQ. Highways to hell: mechanism&#x2010;based management of cytokine storm syndromes. J Allergy Clin Immunol. 2020;146(5):949&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7522622</ArticleId><ArticleId IdType="pubmed">33007328</ArticleId></ArticleIdList></Reference><Reference><Citation>Baig AM. Chronic COVID syndrome: need for an appropriate medical terminology for long&#x2010;COVID and COVID long&#x2010;haulers. J Med Virol. 2020. 10.1002/jmv.26624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26624</ArticleId><ArticleId IdType="pubmed">33095459</ArticleId></ArticleIdList></Reference><Reference><Citation>Helms J, Kremer S, Merdji H, Clere&#x2010;Jehl R, Schenck M, Kummerlen C, et al. Neurologic features in severe SARS&#x2010;CoV&#x2010;2 infection. N Engl J Med. 2020;382(23):2268&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7179967</ArticleId><ArticleId IdType="pubmed">32294339</ArticleId></ArticleIdList></Reference><Reference><Citation>Fotuhi M, Mian A, Meysami S, Raji CA. Neurobiology of COVID&#x2010;19. J Alzheimers Dis. 2020;76(1):3&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7660990</ArticleId><ArticleId IdType="pubmed">32538857</ArticleId></ArticleIdList></Reference><Reference><Citation>Najjar S, Najjar A, Chong DJ, Pramanik BK, Kirsch C, Kuzniecky RI, et al. Central nervous system complications associated with SARS&#x2010;CoV&#x2010;2 infection: integrative concepts of pathophysiology and case reports. J Neuroinflammation. 2020;17(1):231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7406702</ArticleId><ArticleId IdType="pubmed">32758257</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh AK, Bhushan B, Maurya A, Mishra G, Singh SK, Awasthi R. Novel coronavirus disease 2019 (COVID&#x2010;19) and neurodegenerative disorders. Dermatol Ther. 2020;33(4):e13591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7261984</ArticleId><ArticleId IdType="pubmed">32412679</ArticleId></ArticleIdList></Reference><Reference><Citation>Ongur D, Perlis R, Goff D. Psychiatry and COVID&#x2010;19. JAMA. 2020;324(12):1149&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">32960247</ArticleId></ArticleIdList></Reference><Reference><Citation>Vindegaard N, Benros ME. COVID&#x2010;19 pandemic and mental health consequences: systematic review of the current evidence. Brain Behav Immun. 2020;89:531&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7260522</ArticleId><ArticleId IdType="pubmed">32485289</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfefferbaum B, North CS. Mental health and the Covid&#x2010;19 pandemic. N Engl J Med. 2020;383(6):510&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">32283003</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang YT, Yang Y, Li W, Zhang L, Zhang Q, Cheung T, et al. Timely mental health care for the 2019 novel coronavirus outbreak is urgently needed. Lancet Psychiatry. 2020;7(3):228&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7128153</ArticleId><ArticleId IdType="pubmed">32032543</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon JA, Borja SE. The COVID&#x2010;19 pandemic: setting the mental Health Research agenda. Biol Psychiatry. 2020;88(2):130&#x2013;1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233229</ArticleId><ArticleId IdType="pubmed">32425206</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L, Dyer AH, Jones K, Dunne J, Mooney A, Gaffney F, et al. Persistent fatigue following SARS&#x2010;CoV&#x2010;2 infection is common and independent of severity of initial infection. PLoS ONE. 2020;15(11):e0240784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7652254</ArticleId><ArticleId IdType="pubmed">33166287</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC, Conti P. COVID&#x2010;19 and multisystem inflammatory syndrome, or is it Mast cell activation syndrome. J Biol Regul Homeost Agents. 2020;34(5):1633&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">33023287</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatziagelaki E, Adamaki M, Tsilioni I, Dimitriadis G, Theoharides TC. Myalgic encephalomyelitis/chronic fatigue syndrome&#x2010;metabolic disease or disturbed homeostasis due to focal inflammation in the hypothalamus? J Pharmacol Exp Ther. 2018;367(1):155&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">30076265</ArticleId></ArticleIdList></Reference><Reference><Citation>Natelson BH. Myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia: definitions, similarities, and differences. Clin Ther. 2019;41(4):612&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6589349</ArticleId><ArticleId IdType="pubmed">30795933</ArticleId></ArticleIdList></Reference><Reference><Citation>Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: proposed diagnostic criteria. J Allergy Clin Immunol. 2010;126(6):1099&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3753019</ArticleId><ArticleId IdType="pubmed">21035176</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC, Tsilioni I, Ren H. Recent advances in our understanding of mast cell activation &#x2010; or should it be mast cell mediator disorders? Expert Rev Clin Immunol. 2019;15(6):639&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7003574</ArticleId><ArticleId IdType="pubmed">30884251</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC, Valent P, Mast Cells AC. Mastocytosis and related disorders. N Engl J Med. 2015;373(2):163&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">26154789</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazama I. Stabilizing mast cells by commonly used drugs: a novel therapeutic target to relieve post&#x2010;COVID syndrome? Drug Discov Ther. 2020;14(5):259&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">33116043</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC, Boucher W, Spear K. Serum interleukin&#x2010;6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol. 2002;128:344&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">12218373</ArticleId></ArticleIdList></Reference><Reference><Citation>Brockow K, Akin C, Huber M, Metcalfe DD. IL&#x2010;6 levels predict disease variant and extent of organ involvement in patients with mastocytosis. Clin Immunol. 2005;115(2):216&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">15885646</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayado A, Teodosio C, Garcia&#x2010;Montero AC, Matito A, Rodriguez&#x2010;Caballero A, Morgado JM, et al. Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression. Leukemia. 2015;30(1):124&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">26153655</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai A, Jung MY, Olivera A, Gilfillan AM, Prussin C, Kirshenbaum AS, et al. IL&#x2010;6 promotes an increase in human mast cell numbers and reactivity through suppression of suppressor of cytokine signaling 3. J Allergy Clin Immunol. 2016;137(6):1863&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4899186</ArticleId><ArticleId IdType="pubmed">26774658</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang W, Guan W, Chen R, Wang W, Li J, Xu K, Li C, Ai Q, et al. Cancer patients in SARS&#x2010;CoV&#x2010;2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335&#x2013;7. 10.1016/S1470-2045(20)30096-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(20)30096-6</ArticleId><ArticleId IdType="pmc">PMC7159000</ArticleId><ArticleId IdType="pubmed">32066541</ArticleId></ArticleIdList></Reference><Reference><Citation>Cascella M, Di NR, Carbone D, Cuomo GF, Bimonte S, Muzio MR. Chemotherapy&#x2010;related cognitive impairment: mechanisms, clinical features and research perspectives. Recenti Prog Med. 2018;109(11):523&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">30565571</ArticleId></ArticleIdList></Reference><Reference><Citation>Lange M, Joly F. How to identify and manage cognitive dysfunction after breast cancer treatment. J Oncol Pract. 2017;13(12):784&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">29232539</ArticleId></ArticleIdList></Reference><Reference><Citation>Bompaire F, Durand T, Leger&#x2010;Hardy I, Psimaras D, Ricard D. Chemotherapy&#x2010;related cognitive impairment or &lt;&lt;chemobrain&gt;&gt;: concept and state of art. Geriatr Psychol Neuropsychiatr Vieil. 2017;15(1):89&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">28266346</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian SV, Mejia&#x2010;Guevara I, Krishna A. Rethinking policy perspectives on childhood stunting: time to formulate a structural and multifactorial strategy. Matern Child Nutr. 2016;12(Suppl 1):219&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5084745</ArticleId><ArticleId IdType="pubmed">27187918</ArticleId></ArticleIdList></Reference><Reference><Citation>Raffa RB, Duong PV, Finney J, Garber DA, Lam LM, Mathew SS, et al. Is 'chemo&#x2010;fog'/'chemo&#x2010;brain' caused by cancer chemotherapy? J Clin Pharm Ther. 2006;31(2):129&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">16635046</ArticleId></ArticleIdList></Reference><Reference><Citation>Raffa RB. A proposed mechanism for chemotherapy&#x2010;related cognitive impairment ('chemo&#x2010;fog'). J Clin Pharm Ther. 2011;36(3):257&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3249621</ArticleId><ArticleId IdType="pubmed">21545608</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell T, Turton P. 'Chemobrain': concentration and memory effects in people receiving chemotherapy &#x2010; a descriptive phenomenological study. Eur J Cancer Care (Engl). 2011;20(4):539&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">21443746</ArticleId></ArticleIdList></Reference><Reference><Citation>Selamat MH, Loh SY, Mackenzie L, Vardy J. Chemobrain experienced by breast cancer survivors: a meta&#x2010;ethnography study investigating research and care implications. PLoS ONE. 2014;9(9):e108002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4178068</ArticleId><ArticleId IdType="pubmed">25259847</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemobrain BW. An opportunity in cancer survivorship to enhance patient wellness. J Oncol Pract. 2017;13(12):794&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">29232541</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutmann DH. Clearing the fog surrounding Chemobrain. Cell. 2019;176(1&#x2013;2):2&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">30633904</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson FM, Cross AJ, Baraniak AR. A new normal with chemobrain': experiences of the impact of chemotherapy&#x2010;related cognitive deficits in long&#x2010;term breast cancer survivors. Health Psychol Open. 2019;6(1):2055102919832234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6405778</ArticleId><ArticleId IdType="pubmed">30873289</ArticleId></ArticleIdList></Reference><Reference><Citation>Simo M, Rifa&#x2010;Ros X, Rodriguez&#x2010;Fornells A, Bruna J. Chemobrain: a systematic review of structural and functional neuroimaging studies. Neurosci Biobehav Rev. 2013;37(8):1311&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">23660455</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherling CS, Smith A. Opening up the window into &#x201c;chemobrain&#x201d;: a neuroimaging review. Sensors (Basel). 2013;13(3):3169&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3658739</ArticleId><ArticleId IdType="pubmed">23467031</ArticleId></ArticleIdList></Reference><Reference><Citation>Eide S, Feng ZP. Doxorubicin chemotherapy&#x2010;induced &#x201c;chemo&#x2010;brain": meta&#x2010;analysis. Eur J Pharmacol. 2020;881:173078.</Citation><ArticleIdList><ArticleId IdType="pubmed">32505665</ArticleId></ArticleIdList></Reference><Reference><Citation>El&#x2010;Agamy SE, Bdel&#x2010;Aziz AK, Esmat A, Azab SS. Chemotherapy and cognition: comprehensive review on doxorubicin&#x2010;induced chemobrain. Cancer Chemother Pharmacol. 2019;84(1):1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">30955080</ArticleId></ArticleIdList></Reference><Reference><Citation>Ongnok B, Chattipakorn N, Chattipakorn SC. Doxorubicin and cisplatin induced cognitive impairment: the possible mechanisms and interventions. Exp Neurol. 2020;324:113118.</Citation><ArticleIdList><ArticleId IdType="pubmed">31756316</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson EM, Nagaraja S, Ocampo A, Tam LT, Wood LS, Pallegar PN, et al. Methotrexate chemotherapy induces persistent tri&#x2010;glial dysregulation that underlies chemotherapy&#x2010;related cognitive impairment. Cell. 2019;176(1&#x2013;2):43&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6329664</ArticleId><ArticleId IdType="pubmed">30528430</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy D, Burstein R, Kainz V, Jakubowski M, Strassman AM. Mast cell degranulation activates a pain pathway underlying migraine headache. Pain. 2007;130(1&#x2013;2):166&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2045157</ArticleId><ArticleId IdType="pubmed">17459586</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvi E, Marchetti M, Santagata F, Luppi C, Coppo E, Massaia M, et al. Similar neurocognitive patterns in patients treated with lenalidomide: chemobrain effect? Neurocase. 2019;25(6):259&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">31522586</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Lee HJ, Kang H, Kim E&#x2010;H, Lim Y&#x2010;C, Park H, et al. Trastuzumab induced chemobrain, atorvastatin rescued chemobrain with enhanced anticancer effect and without hair loss&#x2010;side effect. J Clin Med. 2019;8(2):234. 10.3390/jcm8020234.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm8020234</ArticleId><ArticleId IdType="pmc">PMC6406319</ArticleId><ArticleId IdType="pubmed">30754707</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren X, Boriero D, Chaiswing L, Bondada S, St Clair DK, Butterfield DA. Plausible biochemical mechanisms of chemotherapy&#x2010;induced cognitive impairment (&#x201c;chemobrain&#x201d;), a condition that significantly impairs the quality of life of many cancer survivors. Biochim Biophys Acta Mol Basis Dis. 2019;1865(6):1088&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6502692</ArticleId><ArticleId IdType="pubmed">30759363</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson EM, Monje M. Emerging mechanistic underpinnings and therapeutic targets for chemotherapy&#x2010;related cognitive impairment. Curr Opin Oncol. 2019;31(6):531&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7205182</ArticleId><ArticleId IdType="pubmed">31449084</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen LD, Ehrlich BE. Cellular mechanisms and treatments for chemobrain: insight from aging and neurodegenerative diseases. EMBO Mol Med. 2020;12(6):e12075.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7278555</ArticleId><ArticleId IdType="pubmed">32346964</ArticleId></ArticleIdList></Reference><Reference><Citation>Christie LA, Acharya MM, Parihar VK, Nguyen A, Martirosian V, Limoli CL. Impaired cognitive function and hippocampal neurogenesis following cancer chemotherapy. Clin Cancer Res. 2012;18(7):1954&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">22338017</ArticleId></ArticleIdList></Reference><Reference><Citation>Leake I. Aberrant adaptive myelination in &#x2018;chemobrain&#x2019;. Nat Rev Neurosci. 2019;20(8):448&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">31168084</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang XM, Walitt B, Saligan L, Tiwari AF, Cheung CW, Zhang ZJ. Chemobrain: a critical review and causal hypothesis of link between cytokines and epigenetic reprogramming associated with chemotherapy. Cytokine. 2015;72(1):86&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4750385</ArticleId><ArticleId IdType="pubmed">25573802</ArticleId></ArticleIdList></Reference><Reference><Citation>Raffa RB. Cancer 'survivor&#x2010;care': II. Disruption of prefrontal brain activation top&#x2010;down control of working memory capacity as possible mechanism for chemo&#x2010;fog/brain (chemotherapy&#x2010;associated cognitive impairment). J Clin Pharm Ther. 2013;38(4):265&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3712332</ArticleId><ArticleId IdType="pubmed">23656522</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren X, St Clair DK, Butterfield DA. Dysregulation of cytokine mediated chemotherapy induced cognitive impairment. Pharmacol Res. 2017;117:267&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">28063894</ArticleId></ArticleIdList></Reference><Reference><Citation>Colonna M, Butovsky O. Microglia function in the central nervous system during health and neurodegeneration. Annu Rev Immunol. 2017;35:441&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8167938</ArticleId><ArticleId IdType="pubmed">28226226</ArticleId></ArticleIdList></Reference><Reference><Citation>Subhramanyam CS, Wang C, Hu Q, Dheen ST. Microglia&#x2010;mediated neuroinflammation in neurodegenerative diseases. Semin Cell Dev Biol. 2019;94:112&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">31077796</ArticleId></ArticleIdList></Reference><Reference><Citation>Voet S, Prinz M, Van LG. Microglia in central nervous system inflammation and multiple sclerosis pathology. Trends Mol Med. 2019;25(2):112&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">30578090</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry VH, Nicoll JA, Holmes C. Microglia in neurodegenerative disease. Nat Rev Neurol. 2010;6(4):193&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">20234358</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM. How neuroinflammation contributes to neurodegeneration. Science. 2016;353(6301):777&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">27540165</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman S, Izzy S, Sen P, Morsett L, El KJ. Microglia in neurodegeneration. Nat Neurosci. 2018;21(10):1359&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6817969</ArticleId><ArticleId IdType="pubmed">30258234</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CS, Arbour N, Manusow J, Montgrain V, Blain M, McCrea E, et al. TLR signaling tailors innate immune responses in human microglia and astrocytes. J Immunol. 2005;175(7):4320&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">16177072</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas G, Medeiros Geraldo LH, Gedeao SN, Viana PM, Regina Souza LF, Carvalho Alcantara GF. Severe acute respiratory syndrome coronavirus 2 (SARS&#x2010;CoV&#x2010;2) and glial cells: insights and perspectives. Brain Behav Immun Health. 2020;7:100127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7423575</ArticleId><ArticleId IdType="pubmed">32838339</ArticleId></ArticleIdList></Reference><Reference><Citation>Murta V, Villarreal A, Ramos AJ. Severe acute respiratory syndrome coronavirus 2 impact on the central nervous system: are astrocytes and microglia main players or merely bystanders? ASN Neuro. 2020;12:1759091420954960.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7476346</ArticleId><ArticleId IdType="pubmed">32878468</ArticleId></ArticleIdList></Reference><Reference><Citation>Steenblock C, Todorov V, Kanczkowski W, Eisenhofer G, Schedl A, Wong ML, et al. Severe acute respiratory syndrome coronavirus 2 (SARS&#x2010;CoV&#x2010;2) and the neuroendocrine stress axis. Mol Psychiatry. 2020;25(8):1611&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7204611</ArticleId><ArticleId IdType="pubmed">32382135</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC. Stress, inflammation, and autoimmunity: the 3 modern Erinyes. Clin Ther. 2020;42(5):742&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7165270</ArticleId><ArticleId IdType="pubmed">32354496</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC. Effect of psychological stress on mast cells. Ann Allergy Asthma Immunol. 2020;125:388&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">32687989</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Ji P, Riopelle RJ, Dow KE. Functional expression of corticotropin&#x2010;releasing hormone (CRH) receptor 1 in cultured rat microglia. J Neurochem. 2002;80:287&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">11902119</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempuraj D, Selvakumar GP, Ahmed ME, Raikwar SP, Thangavel R, Khan A, et al. COVID&#x2010;19, mast cells, cytokine storm, psychological stress, and neuroinflammation. Neuroscientist. 2020;26(5&#x2013;6):402&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">32684080</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendriksen E, van BD ORS, Redegeld FA. Mast cells in neuroinflammation and brain disorders. Neurosci Biobehav Rev. 2017;79:119&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">28499503</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Wang Y, Dong H, Xu Y, Zhang S. Induction of microglial activation by mediators released from mast cells. Cell Physiol Biochem. 2016;38(4):1520&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">27050634</ArticleId></ArticleIdList></Reference><Reference><Citation>Skaper SD, Facci L, Zusso M, Giusti P. Neuroinflammation, mast cells, and glia: dangerous liaisons. Neuroscientist. 2017;23(5):478&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">29283023</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaik&#x2010;Dasthagirisaheb YB, Conti P. The role of mast cells in Alzheimer's disease. Adv Clin Exp Med. 2016;25(4):781&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">27629855</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempuraj D, Mentor S, Thangavel R, Ahmed ME, Selvakumar GP, Raikwar SP, et al. Mast cells in stress, pain, blood&#x2010;brain barrier, neuroinflammation and Alzheimer's disease. Front Cell Neurosci. 2019;13:54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6389675</ArticleId><ArticleId IdType="pubmed">30837843</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen DV, Hanson JE, Sheng M. Microglia in Alzheimer's disease. J Cell Biol. 2018;217(2):459&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5800817</ArticleId><ArticleId IdType="pubmed">29196460</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Dong H, Li N, Zhang S, Sun J, Zhang S, et al. Activated brain mast cells contribute to postoperative cognitive dysfunction by evoking microglia activation and neuronal apoptosis. J Neuroinflammation. 2016;13(1):127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888609</ArticleId><ArticleId IdType="pubmed">27245661</ArticleId></ArticleIdList></Reference><Reference><Citation>Moura DS, Sultan S, Georgin&#x2010;Lavialle S, Barete S, Lortholary O, Gaillard R, et al. Evidence for cognitive impairment in mastocytosis: prevalence, features and correlations to depression. PLoS ONE. 2012;7(6):e39468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3379977</ArticleId><ArticleId IdType="pubmed">22745762</ArticleId></ArticleIdList></Reference><Reference><Citation>Afrin LB, Pohlau D, Raithel M, Haenisch B, Dumoulin FL, Homann J, et al. Mast cell activation disease: an underappreciated cause of neurologic and psychiatric symptoms and diseases. Brain Behav Immun. 2015;50:314&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">26162709</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC. Effect of stress on neuroimmune processes. Clin Ther. 2020;42:1007&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">32451121</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC, Donelan JM, Papadopoulou N, Cao J, Kempuraj D, Conti P. Mast cells as targets of corticotropin&#x2010;releasing factor and related peptides. Trends Pharmacol Sci. 2004;25(11):563&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15491778</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC, Konstantinidou A. Corticotropin&#x2010;releasing hormone and the blood&#x2010;brain&#x2010;barrier. Front Biosci. 2007;12:1615&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">17127408</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiorentino M, Sapone A, Senger S, Camhi SS, Kadzielski SM, Buie TM, et al. Blood&#x2010;brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders. Mol Autism. 2016;7:49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5129651</ArticleId><ArticleId IdType="pubmed">27957319</ArticleId></ArticleIdList></Reference><Reference><Citation>Mastorakos G, Chrousos GP, Weber JS. Recombinant interleukin&#x2010;6 activates the hypothalamic&#x2010;pituitary&#x2010;adrenal axis in humans. J Clin Endocrinol Metab. 1993;77:1690&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">8263159</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempuraj D, Papadopoulou NG, Lytinas M, Huang M, Kandere&#x2010;Grzybowska K, Madhappan B, et al. Corticotropin&#x2010;releasing hormone and its structurally related urocortin are synthesized and secreted by human mast cells. Endocrinology. 2004;145:43&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">14576187</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MH, Perl DP, Nair G, Li W, Maric D, Murray H, et al. Microvascular injury in the brains of patients with Covid&#x2010;19. N Engl J Med. 2020;384(5):481&#x2013;3. 10.1056/NEJMc2033369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2033369</ArticleId><ArticleId IdType="pmc">PMC7787217</ArticleId><ArticleId IdType="pubmed">33378608</ArticleId></ArticleIdList></Reference><Reference><Citation>Nazari S, Azari JA, Mirmoeeni S, Sadeghian S, Heidari ME, Sadeghian S, et al. Central nervous system manifestations in COVID&#x2010;19 patients: a systematic review and meta&#x2010;analysis. Brain Behav. 2021:e02025. 10.1002/brb3.2025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/brb3.2025</ArticleId><ArticleId IdType="pmc">PMC7994971</ArticleId><ArticleId IdType="pubmed">33421351</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID&#x2010;19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID&#x2010;19 cases in the USA. Lancet Psychiatry. 2021;8(2):130&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7820108</ArticleId><ArticleId IdType="pubmed">33181098</ArticleId></ArticleIdList></Reference><Reference><Citation>Baig AM. Deleterious outcomes in long&#x2010;hauler COVID&#x2010;19: the effects of SARS&#x2010;CoV&#x2010;2 on the CNS in chronic COVID syndrome. ACS Chem Nerosci. 2020;11(24):4017&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">33275404</ArticleId></ArticleIdList></Reference><Reference><Citation>Olivera A, Beaven MA, Metcalfe DD. Mast cells signal their importance in health and disease. J Allergy Clin Immunol. 2018;142(2):381&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">29454835</ArticleId></ArticleIdList></Reference><Reference><Citation>Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature. 2008;454(7203):445&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3573758</ArticleId><ArticleId IdType="pubmed">18650915</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozniecki JJ, Dimitriadou V, Lambracht&#x2010;Hall M, Pang X, Theoharides TC. Morphological and functional demonstration of rat dura mast cell&#x2010;neuron interactions in vitro and in vivo . Brain Res. 1999;849:1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">10592282</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall JS, Portales&#x2010;Cervantes L, Leong E. Mast cell responses to viruses and pathogen products. Int J Mol Sci. 2019;20(17):4241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6747121</ArticleId><ArticleId IdType="pubmed">31480219</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC. Potential association of mast cells with COVID&#x2010;19. Ann Allergy Asthma Immunol. 2020;126(3):217&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7644430</ArticleId><ArticleId IdType="pubmed">33161155</ArticleId></ArticleIdList></Reference><Reference><Citation>Motta Junior JDS, Miggiolaro AFRD, Nagashima S, de Paula CBV, Baena CP, Scharfstein J, et al. Mast cells in alveolar septa of COVID&#x2010;19 patients: a pathogenic pathway that may link interstitial edema to Immunothrombosis. Front Immunol. 2020;11:574862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7530169</ArticleId><ArticleId IdType="pubmed">33042157</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. High expression of ACE2 receptor of 2019&#x2010;nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12(1):8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7039956</ArticleId><ArticleId IdType="pubmed">32094336</ArticleId></ArticleIdList></Reference><Reference><Citation>Alysandratos KD, Asadi S, Angelidou A, Zhang B, Sismanopoulos N, Yang H, et al. Neurotensin and CRH interactions augment human mast cell activation. PLoS One. 2012;7(11):e48934.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3498358</ArticleId><ArticleId IdType="pubmed">23155429</ArticleId></ArticleIdList></Reference><Reference><Citation>Asadi S, Alysandratos KD, Angelidou A, Miniati A, Sismanopoulos N, Vasiadi M, et al. Substance P (SP) induces expression of functional corticotropin&#x2010;releasing hormone receptor&#x2010;1 (CRHR&#x2010;1) in human mast cells. J Invest Dermatol. 2012;132(2):324&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3471564</ArticleId><ArticleId IdType="pubmed">22089831</ArticleId></ArticleIdList></Reference><Reference><Citation>Taracanova A, Alevizos M, Karagkouni A, Weng Z, Norwitz E, Conti P, et al. SP and IL&#x2010;33 together markedly enhance TNF synthesis and secretion from human mast cells mediated by the interaction of their receptors. Proc Natl Acad Sci U S A. 2017;114(20):E4002&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5441798</ArticleId><ArticleId IdType="pubmed">28461492</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegler CGK, Allon SJ, Nyquist SK, Mbano IM, Miao VN, Tzouanas CN, et al. SARS&#x2010;CoV&#x2010;2 receptor ACE2 is an interferon&#x2010;stimulated gene in human airway epithelial Cells and is detected in specific cell subsets across tissues. Cell. 2020;181(5):1016&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7252096</ArticleId><ArticleId IdType="pubmed">32413319</ArticleId></ArticleIdList></Reference><Reference><Citation>Dietrich N, Rohde M, Geffers R, Kroger A, Hauser H, Weiss S, et al. Mast cells elicit proinflammatory but not type I interferon responses upon activation of TLRs by bacteria. Proc Natl Acad Sci U S A. 2010;107(19):8748&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2889343</ArticleId><ArticleId IdType="pubmed">20421474</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukai K, Tsai M, Saito H, Galli SJ. Mast cells as sources of cytokines, chemokines, and growth factors. Immunol Rev. 2018;282(1):121&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5813811</ArticleId><ArticleId IdType="pubmed">29431212</ArticleId></ArticleIdList></Reference><Reference><Citation>Bawazeer MA, Theoharides TC. IL&#x2010;33 stimulates human mast cell release of CCL5 and CCL2 via MAPK and NF&#x2010;kappaB, inhibited by methoxyluteolin. Eur J Pharmacol. 2019;865:172760.</Citation><ArticleIdList><ArticleId IdType="pubmed">31669588</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandere&#x2010;Grzybowska K, Letourneau R, Kempuraj D, Donelan J, Poplawski S, Boucher W, et al. IL&#x2010;1 induces vesicular secretion of IL&#x2010;6 without degranulation from human mast cells. J Immunol. 2003;171(9):4830&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">14568962</ArticleId></ArticleIdList></Reference><Reference><Citation>Taracanova A, Tsilioni I, Conti P, Norwitz ER, Leeman SE, Theoharides TC. Substance P and IL&#x2010;33 administered together stimulate a marked secretion of IL&#x2010;1beta from human mast cells, inhibited by methoxyluteolin. Proc Natl Acad Sci U S A. 2018;115(40):E9381&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6176605</ArticleId><ArticleId IdType="pubmed">30232261</ArticleId></ArticleIdList></Reference><Reference><Citation>Saluja R, Khan M, Church MK, Maurer M. The role of IL&#x2010;33 and mast cells in allergy and inflammation. Clin Transl Allergy. 2015;5:33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4588911</ArticleId><ArticleId IdType="pubmed">26425339</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC, Leeman SE. Effect of IL&#x2010;33 on de novo synthesized mediators from human mast cells. J Allergy Clin Immunol. 2019;143:451.</Citation><ArticleIdList><ArticleId IdType="pubmed">30390921</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti P, Caraffa A, Tete G, Gallenga CE, Ross R, Kritas SK, et al. Mast cells activated by SARS&#x2010;CoV&#x2010;2 release histamine which increases IL&#x2010;1 levels causing cytokine storm and inflammatory reaction in COVID&#x2010;19. J Biol Regul Homeost Agents. 2020;34(5):1629&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">32945158</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Asadi S, Weng Z, Sismanopoulos N, Theoharides TC. Stimulated human mast cells secrete mitochondrial components that have autocrine and paracrine inflammatory actions. PLoS One. 2012;7(12):e49767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3524249</ArticleId><ArticleId IdType="pubmed">23284625</ArticleId></ArticleIdList></Reference><Reference><Citation>Scozzi D, Cano M, Ma L, Zhou D, Zhu JH, O'Halloran JA, et al. Circulating mitochondrial DNA is an early indicator of severe illness and mortality from COVID&#x2010;19. JCI Insight. 2021;6(4):e143299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7934921</ArticleId><ArticleId IdType="pubmed">33444289</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins LV, Hajizadeh S, Holme E, Jonsson IM, Tarkowski A. Endogenously oxidized mitochondrial DNA induces in vivo and in vitro inflammatory responses. J Leukoc Biol. 2004;75(6):995&#x2013;1000.</Citation><ArticleIdList><ArticleId IdType="pubmed">14982943</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun S, Sursal T, Adibnia Y, Zhao C, Zheng Y, Li H, et al. Mitochondrial DAMPs increase endothelial permeability through neutrophil dependent and independent pathways. PLoS One. 2013;8(3):e59989.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3603956</ArticleId><ArticleId IdType="pubmed">23527291</ArticleId></ArticleIdList></Reference><Reference><Citation>Demopoulos C, Antonopoulou S, Theoharides TC. COVID&#x2010;19, microthromboses, inflammation and platelet activating factor. Biofactors. 2020;46(6):927&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">33296106</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC, Antonopoulou S, Demopoulos CA. Coronavirus 2019, microthromboses, and platelet activating factor. Clin Ther. 2020. 42(10):1850&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7430296</ArticleId><ArticleId IdType="pubmed">32883529</ArticleId></ArticleIdList></Reference><Reference><Citation>Iannaccone G, Scacciavillani R, Del Buono MG, Camilli M, Ronco C, Lavie CJ, et al. Weathering the cytokine storm in COVID&#x2010;19: therapeutic implications. Cardiorenal Med. 2020;10(5):277&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7360507</ArticleId><ArticleId IdType="pubmed">32599589</ArticleId></ArticleIdList></Reference><Reference><Citation>Richman S, Morris MC, Broderick G, Craddock TJA, Klimas NG, Fletcher MA. Pharmaceutical interventions in chronic fatigue syndrome: a literature&#x2010;based commentary. Clin Ther. 2019;41(5):798&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6543846</ArticleId><ArticleId IdType="pubmed">30871727</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamilloux Y, Henry T, Belot A, Viel S, Fauter M, el Jammal T, et al. Should we stimulate or suppress immune responses in COVID&#x2010;19? Cytokine and anti&#x2010;cytokine interventions. Autoimmun Rev. 2020;19(7):102567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7196557</ArticleId><ArticleId IdType="pubmed">32376392</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronconi G, Tete G, Kritas SK, Gallenga CE, Al Caraffa RR, Conti P. SARS&#x2010;CoV&#x2010;2, which induces COVID&#x2010;19, causes Kawasaki&#x2010;like disease in children: role of pro&#x2010;inflammatory and anti&#x2010;inflammatory cytokines. J Biol Regul Homeost Agents. 2020;34(3):767&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">32476380</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez&#x2010;Lopez N, StLouis D, Lehr MA, Sanchez&#x2010;Rodriguez EN, Renas&#x2010;Hernandez M. Immune cells in term and preterm labor. Cell Mol Immunol. 2014;11(6):571&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4220837</ArticleId><ArticleId IdType="pubmed">24954221</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC, Conti P. Dexamethasone for COVID&#x2010;19? not so fast. J Biol Regul Homeost Agents. 2020;34(3):1241&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">32551464</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC. COVID&#x2010;19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin. Biofactors. 2020;46(3):306&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7267424</ArticleId><ArticleId IdType="pubmed">32339387</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempuraj D, Madhappan B, Christodoulou S, Boucher W, Cao J, Papadopoulou N, et al. Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. Br J Pharmacol. 2005;145:934&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1576204</ArticleId><ArticleId IdType="pubmed">15912140</ArticleId></ArticleIdList></Reference><Reference><Citation>Seelinger G, Merfort I, Schempp CM. Anti&#x2010;oxidant, anti&#x2010;inflammatory and anti&#x2010;allergic activities of luteolin. Planta Med. 2008;74(14):1667&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">18937165</ArticleId></ArticleIdList></Reference><Reference><Citation>Calis Z, Mogulkoc R, Baltaci AK. The roles of flavonoles/flavonoids in neurodegeneration and neuroinflammation. Mini Rev Med Chem. 2020;20(15):1475&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">31288717</ArticleId></ArticleIdList></Reference><Reference><Citation>Jager AK, Saaby L. Flavonoids and the CNS. Molecules. 2011;16(2):1471&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6259921</ArticleId><ArticleId IdType="pubmed">21311414</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyva&#x2010;Lopez N, Gutierrez&#x2010;Grijalva EP, Mbriz&#x2010;Perez DL, Heredia JB. Flavonoids as cytokine modulators: a possible therapy for inflammation&#x2010;related diseases. Int J Mol Sci. 2016;17(6):921. 10.3390/ijms17060921.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms17060921</ArticleId><ArticleId IdType="pmc">PMC4926454</ArticleId><ArticleId IdType="pubmed">27294919</ArticleId></ArticleIdList></Reference><Reference><Citation>Harwood M, Nielewska&#x2010;Nikiel B, Borzelleca JF, Flamm GW, Williams GM, Lines TC. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol. 2007;45(11):2179&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">17698276</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto T. Safety of quercetin for clinical application (review). Int J Mol Med. 2005;16(2):275&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">16012761</ArticleId></ArticleIdList></Reference><Reference><Citation>Taliou A, Zintzaras E, Lykouras L, Francis K. An open&#x2010;label pilot study of a formulation containing the anti&#x2010;inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders. Clin Ther. 2013;35(5):592&#x2013;602.</Citation><ArticleIdList><ArticleId IdType="pubmed">23688534</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC, Conti P, Economu M. Brain inflammation, neuropsychiatric disorders, and immunoendocrine effects of luteolin. J Clin Psychopharmacol. 2014;34(2):187&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">24525647</ArticleId></ArticleIdList></Reference><Reference><Citation>Andres S, Pevny S, Ziegenhagen R, Bakhiya N, Sch&#xe4;fer B, Hirsch&#x2010;Ernst KI, et al. Safety aspects of the use of quercetin as a dietary supplement. Mol Nutr Food Res. 2018;62(1). 10.1002/mnfr.201700447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mnfr.201700447</ArticleId><ArticleId IdType="pubmed">29127724</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo M, Moccia S, Spagnuolo C, Tedesco I, Russo GL. Roles of flavonoids against coronavirus infection. Chem Biol Interact. 2020;328:109211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7385538</ArticleId><ArticleId IdType="pubmed">32735799</ArticleId></ArticleIdList></Reference><Reference><Citation>Derosa G, Maffioli P, D'Angelo A, Di PF. A role for quercetin in coronavirus disease 2019 (COVID&#x2010;19). Phytother Res. 2021;35(3):1230&#x2013;6. 10.1002/ptr.6887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ptr.6887</ArticleId><ArticleId IdType="pmc">PMC7675685</ArticleId><ArticleId IdType="pubmed">33034398</ArticleId></ArticleIdList></Reference><Reference><Citation>Calis Z, Mogulkoc R, Baltaci AK. The roles of flavonols/flavonoids in neurodegeneration and neuroinflammation. Mini Rev Med Chem. 2020;20(15):1475&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">31288717</ArticleId></ArticleIdList></Reference><Reference><Citation>Devi SA, Chamoli A. Polyphenols as an effective therapeutic intervention against cognitive decline during normal and pathological brain aging. Adv Exp Med Biol. 2020;1260:159&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">32304034</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang S, Kelley KW, Johnson RW. Luteolin reduces IL&#x2010;6 production in microglia by inhibiting JNK phosphorylation and activation of AP&#x2010;1. Proc Natl Acad Sci U S A. 2008;105(21):7534&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2396685</ArticleId><ArticleId IdType="pubmed">18490655</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel AB, Tsilioni I, Leeman SE, Theoharides TC. Neurotensin stimulates sortilin and mTOR in human microglia inhibitable by methoxyluteolin, a potential therapeutic target for autism. Proc Natl Acad Sci U S A. 2016;113:E7049&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5111711</ArticleId><ArticleId IdType="pubmed">27663735</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng Z, Patel AB, Panagiotidou S, Theoharides TC. The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells. J Allergy Clin Immunol. 2015;135(4):1044&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4388775</ArticleId><ArticleId IdType="pubmed">25498791</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel AB, Theoharides TC. Methoxyluteolin inhibits neuropeptide&#x2010;stimulated proinflammatory mediator release via mTOR activation from human mast cells. J Pharmacol Exp Ther. 2017;361(3):462&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">28404689</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashaari Z, Hadjzadeh MA, Hassanzadeh G, Alizamir T, Yousefi B, Keshavarzi Z, et al. The flavone Luteolin improves central nervous system disorders by different mechanisms: a review. J Mol Neurosci. 2018;65(4):491&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">30083786</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempuraj D, Thangavel R, Kempuraj DD, Ahmed ME, Selvakumar GP, Raikwar SP, et al. Neuroprotective effects of flavone luteolin in neuroinflammation and neurotrauma. Biofactors. 2020. 10.1002/biof.1687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/biof.1687</ArticleId><ArticleId IdType="pubmed">33098588</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC, Stewart JM, Hatziagelaki E, Kolaitis G. Brain &#x201c;fog,&#x201d; inflammation and obesity: key aspects of 2 neuropsychiatric disorders improved by luteolin. Front Neurosci. 2015;9:225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4490655</ArticleId><ArticleId IdType="pubmed">26190965</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezai&#x2010;Zadeh K, Douglas SR, Bai Y, Tian J, Hou H, Mori T, et al. Flavonoid&#x2010;mediated presenilin&#x2010;1 phosphorylation reduces Alzheimer's disease beta&#x2010;amyloid production. J Cell Mol Med. 2009;13(3):574&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2671567</ArticleId><ArticleId IdType="pubmed">18410522</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon Y. Luteolin as a potential preventive and therapeutic candidate for Alzheimer's disease. Exp Gerontol. 2017;95:39&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">28528007</ArticleId></ArticleIdList></Reference><Reference><Citation>Delgado A, Cholevas C, Theoharides TC. Neuroinflammation in Alzheimer's disease and beneficial action of luteolin. Biofactors. 2021. 10.1002/biof.1714.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/biof.1714</ArticleId><ArticleId IdType="pubmed">33615581</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Wang H, Cheng H, Che Z. Ameliorating effect of luteolin on memory impairment in an Alzheimer's disease model. Mol Med Rep. 2016;13(5):4215&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4838167</ArticleId><ArticleId IdType="pubmed">27035793</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu X, Zhang J, Guo L, Xu Y, Sun L, Wang S, et al. Protective role of luteolin against cognitive dysfunction induced by chronic cerebral hypoperfusion in rats. Pharmacol Biochem Behav. 2014;126:122&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">25220684</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC. Luteolin supplements: all that glitters is not gold. Biofactors. 2020. 10.1002/biof.1689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/biof.1689</ArticleId><ArticleId IdType="pubmed">33159817</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsilioni I, Taliou A, Francis K, Theoharides TC. Children with autism Spectrum disorders, who improved with a luteolin containing dietary formulation, show reduced serum levels of TNF and IL&#x2010;6. Transl Psychiatry. 2015;5:e647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5545641</ArticleId><ArticleId IdType="pubmed">26418275</ArticleId></ArticleIdList></Reference><Reference><Citation>Beauchamp GK, Keast RS, Morel D, Lin J, Pika J, Han Q, et al. Phytochemistry: ibuprofen&#x2010;like activity in extra&#x2010;virgin olive oil. Nature. 2005;437(7055):45&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16136122</ArticleId></ArticleIdList></Reference><Reference><Citation>Angeloni C, Malaguti M, Barbalace MC, Hrelia S. Bioactivity of olive oil phenols in neuroprotection. Int J Mol Sci. 2017;18(11):2230. 10.3390/ijms18112230.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18112230</ArticleId><ArticleId IdType="pmc">PMC5713200</ArticleId><ArticleId IdType="pubmed">29068387</ArticleId></ArticleIdList></Reference><Reference><Citation>Casamenti F, Stefani M. Olive polyphenols: new promising agents to combat aging&#x2010;associated neurodegeneration. Expert Rev Neurother. 2017;17(4):345&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">27762153</ArticleId></ArticleIdList></Reference><Reference><Citation>Omar SH, Scott CJ, Hamlin AS, Obied HK. Olive biophenols reduces Alzheimer's pathology in SH&#x2010;SY5Y cells and APPswe mice. Int J Mol Sci. 2018;20(1):125. 10.3390/ijms20010125.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20010125</ArticleId><ArticleId IdType="pmc">PMC6337485</ArticleId><ArticleId IdType="pubmed">30598025</ArticleId></ArticleIdList></Reference><Reference><Citation>Calahorra J, Shenk J, Wielenga VH, Verweij V, Geenen B, Dederen PJ, et al. Hydroxytyrosol, the major phenolic compound of olive oil, as an acute therapeutic strategy after ischemic stroke. Nutrients. 2019;11(10):2430. 10.3390/nu11102430.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11102430</ArticleId><ArticleId IdType="pmc">PMC6836045</ArticleId><ArticleId IdType="pubmed">31614692</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalatbary AR. Olive oil phenols and neuroprotection. Nutr Neurosci. 2013;16(6):243&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">23406576</ArticleId></ArticleIdList></Reference><Reference><Citation>Marquez&#x2010;Martin A, de La PR, Fernandez&#x2010;Arche A, Ruiz&#x2010;Gutierrez V, Yaqoob P. Modulation of cytokine secretion by pentacyclic triterpenes from olive pomace oil in human mononuclear cells. Cytokine. 2006;36(5&#x2013;6):211&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17292619</ArticleId></ArticleIdList></Reference><Reference><Citation>Hornedo&#x2010;Ortega R, Cerezo AB, de Pablos RM, Krisa S, Richard T, Garc&#xed;a&#x2010;Parrilla MC, et al. Phenolic compounds characteristic of the Mediterranean diet in mitigating microglia&#x2010;mediated neuroinflammation. Front Cell Neurosci. 2018;12:373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6206263</ArticleId><ArticleId IdType="pubmed">30405355</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertelli M, Kiani AK, Paolacci S, Manara E, Kurti D, Dhuli K, et al. Hydroxytyrosol: a natural compound with promising pharmacological activities. J Biotechnol. 2020;309:29&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">31884046</ArticleId></ArticleIdList></Reference><Reference><Citation>The Lancet PH . Post&#x2010;COVID&#x2010;19 spending. Lancet Planet Health. 2020;4(5):e168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7237175</ArticleId><ArticleId IdType="pubmed">32442486</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>